OLMA News and Press, Olema Pharmaceuticals Inc. From 11/28/23

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...

2023-11-28 11:52:30 ET Summary Today, we revisit Olema Pharmaceuticals, Inc. for the first time in two years. Olema is a clinical-stage biotech company focused on developing therapies for women's cancers. Their primary product candidate, palazestrant, has been granted FDA Fast Tra...

2023-11-27 13:27:19 ET More on Markets BMO Capital Markets sets base-case S&P 500 target of 5,100 for 2024 Rate cuts, S&P upside and oil prices among BofA's key themes for 2024 VanEck highlights mid-caps as a potential sweet spot for investors For fur...

2023-11-22 17:09:08 ET Gainers: Aurora Innovation ( AUR ) +2% . Innodata  ( INOD ) +2% . The Vita Coco Company ( COCO ) +2% . Immunovant ( IMVT ) +2% . The RealReal ( REAL ) +2% . Losers: BioCryst Pharmaceuticals ( ...

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.22% on the day to $13.25. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapie...

Olema Pharmaceuticals Inc. (OLMA) is expected to report $-0.51 for Q3 2023

2023-11-07 18:05:15 ET Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q3 GAAP EPS of -$0.48. Cash, cash equivalents and marketable securities position of $276.9 million as of September 30, 2023. For further details see: Olema Pharmaceuticals GAAP E...

OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarter New clinical data for palazestrant (OP-1250) in combination with CDK4/6 inhibitors to be presented at the 2023 San Antonio Breast...